International Study on Syncope of Uncertain Etiology 2: the management of patients with suspected or certain neurally mediated syncope after the initial evaluation Rationale and study design

被引:6
作者
Brignole, M [1 ]
Sutton, R [1 ]
Menozzi, C [1 ]
Moya, A [1 ]
Garcia-Civera, R [1 ]
Benditt, D [1 ]
Vardas, P [1 ]
Wieling, W [1 ]
Andresen, D [1 ]
Migliorini, R [1 ]
Hollinworth, D [1 ]
机构
[1] Osped Tigullio, Dept Cardiol, I-16033 Lavagna, Italy
来源
EUROPACE | 2003年 / 5卷 / 03期
关键词
syncope; neurally mediated syncope; electrocardigraphic; monitoring; implantable loop recorder;
D O I
10.1016/S1099-5129(03)00048-5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Study design Multi-centre, prospective observational study Objectives Main objective is to verify the value of implantable loop recorder (ILR) in assessing the mechanism of syncope and the efficacy of the ILR-guided therapy after syncope recurrence. Inclusion criteria Patients who met the following criteria are included: suspected or definite neurally mediated syncope based on initial evaluation; greater than or equal to3 syncope episodes in the last 2 years; severe clinical presentation of syncope requiring treatment initiation in the judgement of the investigator and age >30 years. Exclusion criteria Patients with one or more of the following are excluded: carotid sinus syndrome; suspected or definite heart disease and high likelihood of cardiac syncope; symptomatic orthostatic hypotension diagnosed by standing blood pressure measurement; loss of consciousness different from syncope (e.g. epilepsy, psychiatric, metabolic, drop-attack, TIA, intoxication, cataplexy) and subclavian steal syndrome. End-points The primary end-points are the ECG-documented syncopal events and the syncope recurrences after application of ILR-guided therapy. Sample size and duration A minimum of 400 patients will be enrolled during an anticipated period of 3 years. (C) 2003 The European Society of Cardiology. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:317 / 321
页数:5
相关论文
共 8 条
[1]   Permanent cardiac pacing versus medical treatment for the prevention of recurrent vasovagal syncope - A multicenter, randomized, controlled trial [J].
Ammirati, F ;
Colivicchi, F ;
Santini, M .
CIRCULATION, 2001, 104 (01) :52-57
[2]   Guidelines on management (diagnosis and treatment) of syncope [J].
Brignole, M ;
Alboni, P ;
Benditt, D ;
Bergfeldt, L ;
Blanc, JJ ;
Thomsen, PEB ;
van Dijk, JG ;
Fitzpatrick, A ;
Hohnloser, S ;
Janousek, J ;
Kapoor, W ;
Kenny, RA ;
Kulakowski, P ;
Moya, A ;
Raviele, A ;
Sutton, R ;
Theodorakis, G ;
Wieling, W .
EUROPEAN HEART JOURNAL, 2001, 22 (15) :1256-1306
[3]  
Brignole M, 1997, CIRCULATION, V96, P3921
[4]   New classification of haemodynamics of vasovagal syncope: beyond the VASIS classification - Analysis of the pre-syncopal phase of the tilt test without and with nitroglycerin challenge [J].
Brignole, M ;
Menozzi, C ;
Del Rosso, A ;
Costa, S ;
Gaggioli, G ;
Bottoni, N ;
Bartoli, P ;
Sutton, R .
EUROPACE, 2000, 2 (01) :66-76
[5]   The North American Vasovagal Pacemaker Study (VPS) - A randomized trial of permanent cardiac pacing for the prevention of vasovagal syncope [J].
Connolly, SJ ;
Sheldon, R ;
Roberts, RS ;
Gent, M .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1999, 33 (01) :16-20
[6]   Randomized assessment of syncope trial - Conventional diagnostic testing versus a prolonged monitoring strategy [J].
Krahn, AD ;
Klein, GJ ;
Yee, R ;
Skanes, AC .
CIRCULATION, 2001, 104 (01) :46-51
[7]   Mechanism of syncope in patients with isolated syncope and in patients with tilt-positive syncope [J].
Moya, A ;
Brignole, M ;
Menozzi, C ;
Garcia-Civera, R ;
Tognarini, S ;
Mont, L ;
Botto, G ;
Giada, F ;
Cornacchia, D .
CIRCULATION, 2001, 104 (11) :1261-1267
[8]  
Sutton R, 2000, CIRCULATION, V102, P294